Disclosed herein are compositions and methods for use in therapeutic procedures. Use of a “fast-acting” botulinum toxin for cosmetic treatment and/or to prevent or reduce scarring. “Fast-acting” refers to a botulinum toxin that produces effects in the patient more rapidly than those produced by, for example, a botulinum neurotoxin type A. The “fast-acting” botulinum toxin, for example, type E.

Non-thermal Atmospheric Plasma (NAP) from a plasma source is mixed with a liquid medium and the resulting compound is applied to the scalp to treat hair loss. The NAP-medium compound may be applied to the surface of the scalp, or produced in situ, or injected into the scalp.

The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.

A method of reshaping a body part including the step of injecting a quantity of filler material into a subperiosteal plane of a facial region thereby depositing a body of filler between the periosteum and bone of the facial region. The method includes the step of piercing a periosteum of the facial region with a syringe. The method includes the step of drawing backwards a plunger of the syringe to ascertain whether a tip of a needle of the syringe is within a blood vessel. The filler may include a hyaluronic acid gel. The method of reshaping a body part includes the step of applying pressure to the body of filler to adjust a shape of the body of filler. The step of injecting is repeated in the following order of priority: first the temporal line of fusion, second the zygoma, third the malar, and fourth the jaw line.

The present invention relates to a microneedle comprising a plurality of portions, wherein the plurality of portions comprise a distal end portion and a proximal end portion, at least two of the plurality of portions are made of different polymers, and the distal end portion is made of at least one polymer with high swellability and high viscoelasticity.

The present disclosure discloses a novel use of genistein, epigallocatechin gallate (EGCG), derivatives thereof, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof and solvates thereof. A composition containing genistein, epigallocatechin gallate, derivatives thereof isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof or solvates thereof reduces the expression of factors related to increase of melanin producing ability, reduces the expression of senescence marker proteins and regulates the expression of enzymes involved in melanin production, and thus may have an effect of rejuvenating cells including melanocytes.

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

The present invention relates to a method for crosslinking hyaluronic acid, a method for preparing an injectable hydrogel, the hydrogel thus obtained and its use.

Disclosed are a method of promoting hair growth or preventing hair loss in a mammal. In one aspect, the method includes administering interdermally or subcutaneously an agent containing an active ingredient comprising bFGF and a pharmaceutically acceptable substance, wherein bFGF is administered in a dose of 1 μg to 100 μg per 1 cm.sup.2 of the target area of hair growth treatment or hair loss prevention and a composition for use in the method.

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.